GlassScriptPhysician profile
Kaushal R Patel
NPI 1841438645
$4,637.86
in general payments reported to CMS, 2019-2025
28 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,712 · 2021: $308 · 2022: $467 · 2023: $632 · 2024: $305 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043 · Consulting Fee: $80.00 · Education: $27.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.46 |
| Consulting Fee | $80.00 |
| Education | $27.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $2,656.26 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $293.55 | 2024-2025 | Tavneos, Krystexxa |
| Ardelyx, INC. | $161.46 | 2023-2025 | Ibsrela |
| Abbott Laboratories | $150.24 | 2025 | Gallant |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2022 | |
| Scpharmaceuticals INC. | $113.29 | 2025 | |
| Baxter Healthcare | $110.77 | 2021-2023 | Renal - Acute |
| Glaxosmithkline, LLC. | $98.71 | 2021-2023 | Benlysta |
| Akebia Therapeutics INC | $96.90 | 2024-2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $95.67 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $91.95 | 2022-2023 | Acthar |
| Fresenius USA Marketing, INC. | $75.00 | 2023-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $74.32 | 2023-2025 | |
| Abiomed | $64.30 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $58.19 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.47 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $39.73 | 2025 | Tarpeyo |
| Recor Medical INC | $24.86 | 2025 | Paradise Ultrasound Renal Denervation System |
| Aurinia Pharma U.S., INC. | $22.07 | 2021 | |
| Opko Pharmaceuticals, LLC | $20.11 | 2025 | Rayaldee |
| Philips North America LLC | $19.61 | 2019 | |
| Dentsply Sirona INC | $17.39 | 2023 | Suresmile |
| Nxstage Medical, INC. | $17.28 | 2019 | |
| Horizon Therapeutics Plc | $17.24 | 2023 | Krystexxa |
| Ultragenyx Pharmaceutical INC. | $14.55 | 2021 | |
| Benco Dental Supply Co. | $11.94 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaushal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.